Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
13 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Tanai Therapeutics from Gent, company number BE1002228546, closed financial year 2025 with a result of € -2.5 million after tax. For that financial year Tanai Therapeutics recorded a gross margin of € -528,205 and equity of € 3.6 million. Compared with financial year 2024, the result moved from € -1.8 million to € -2.5 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 22, 2026.
€ 3.6 million
▼ 41% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2.5 million
▼ 38 % more loss than in 2024
Profit after tax over the fiscal year.
€ 2.7 million
▼ 43% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -4.3 million.
People and assets in 2025
€ 5,964
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 315,766
▲ 287% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € -224,811 | € -528,205 | ▼ € 303,393 |
| Profit after taxes | € -1,804,982 | € -2,488,115 | ▼ € 683,133 |
| Equity | € 6,045,018 | € 3,556,903 | ▼ 41% |
| Total debts | € 81,669 | € 315,766 | ▲ 287% |
| Cash | € 4,796,078 | € 2,726,706 | ▼ 43% |
| Retained profit | € -1,804,982 | € -4,293,097 | ▼ € 2.5 million |
| Balance sheet total | € 6,126,687 | € 3,872,669 | ▼ 37% |
Key figures of Tanai Therapeutics, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Tanai Therapeutics?
What happened at Tanai Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- PROsVenture BV stepped down as director. NBB
- Johanne Hendrikke Ellenbroek stepped down as director. NBB
- Carla Maria Coleta Snoeck stepped down as director. NBB
- Shelley Jane Margetson stepped down as director. NBB
- QBic Venture Partners III NV stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2.5 million. Source: NBB ↗
- PROsVenture BV became a director. NBB
- Johanne Hendrikke Ellenbroek became a director. NBB
In short
From € 1.8 million loss in 2024 to € 2.5 million loss in 2025.
Management
The stake of VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY, V-Bio Fund 2, QBIC III FUND comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Tanai TherapeuticsThe shares are held by VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY (22.9%), V-Bio Fund 2 (19.8%) and QBIC III FUND (19.1%).
Directors
According to the 2025 annual accounts
Carla Maria Coleta Snoeck
Director
since 2023 · until 2029
since 2024 · until 2031
Johanne Hendrikke Ellenbroek
Director
since 2024 · until 2030
Shelley Jane Margetson
Director
since 2023 · until 2029
Director · represented by Sara Vandenwijngaert
Also active at: RheaVita, VoxelSensors, AnimAb, AmphiStar, weave.ly, Swave, QBIC III FUND, THERAtRAME +2 more
since 2023 · until 2029
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Pieter van Reysschootlaan 2 box 104
9051 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 13 companies are registered at this address.
All companies at this address →CD-Vastgoed
€ 437,585 gross margin · 2025
V-BIO PARTNERS 1
€ -2,244 gross margin · 2025
V-BIO MANAGEMENT 1
€ 822,886 revenue · 2025
V-Bio Fund 1
€ -903,749 gross margin · 2025
V-Bio Co-Invest 1-1
€ -16,692 gross margin · 2025
+8 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
COMBELL-AS, BE
Website info
Features
Security
Details
- Company number
- 1002.228.546
- VAT number
- BE 1002.228.546
- Registered office
- Pieter van Reysschootlaan 2 bus 104, 9051 Gent
- Names & denominations
- Tanai Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 13 November 2023
- Peppol
- Active · Active since 2 Jan 2026
- Contact
- dokterlagast.be
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied